Cardiac Safety Services Market Size, Demand and Forecast 2034
Global Cardiac Safety Services Market Growth, Size, Trends Analysis – By Service, By Type, By End User-Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Aug-2025 | Report ID: HLCA25262 | Pages: 1 - 222 | Formats*: |
| Category : Healthcare | |||
Global Cardiac Safety Services Market Introduction and Overview
According to SPER Market Research, the Global Cardiac Safety Services Market is estimated to reach USD 3118.99 million by 2034 with a CAGR of 12.34%.
The report includes an in-depth analysis of the Global Cardiac Safety Services Market, including market size and trends, product mix, Applications, and supplier analysis. The Global Cardiac Safety Services Market is expected to be worth USD 974.25 million in 2024, with a CAGR of 12.34% between 2025 and 2034. The growth of the Cardiac Safety Services Market is fueled by the increasing demand for rapid, accurate, and real-time cardiac monitoring solutions, particularly in managing chronic conditions such as cardiovascular diseases and related comorbidities. The rising emphasis on continuous monitoring and home-based healthcare has driven the adoption of portable and wearable ECG and telemetry devices. Technological advancements in data analytics, wireless communication, and biosignal processing have enabled the development of highly sensitive, compact, and patient-friendly cardiac monitoring systems. Furthermore, the integration of these solutions with digital health platforms and smartphones is enhancing accessibility and patient engagement. Growing investments in clinical research, along with heightened awareness of early cardiac risk detection and preventive care, are further propelling the expansion of the cardiac safety services market.
By Service Insights
ECG/Holter monitors segment holds a leading position in the cardiac safety services market. Electrocardiogram (ECG) and Holter monitors are essential tools for continuous cardiac monitoring, allowing for real-time detection of arrhythmias, ischemic events, and other cardiovascular abnormalities. Their broad adoption is driven by their effectiveness in delivering detailed and uninterrupted heart rate data, which is critical for accurate diagnosis and risk assessment. Advances in sensor technology, longer battery life, and the integration of wireless data transmission have significantly enhanced the performance, convenience, and appeal of these monitoring devices in both clinical and remote settings.
By Type Insights
Integrated segment holds a dominant position in the cardiac safety services market. This is mostly because of the rising need for all-inclusive, multipurpose cardiac monitoring systems that increase precision, expedite procedures, and promote patient comfort. Integrated systems combine multiple diagnostic tools—such as ECG, blood pressure monitoring, and imaging—into a single, unified platform, making them highly effective for conducting thorough cardiac assessments. Advancements like cloud-based data storage, real-time analytics, and seamless integration with electronic health records (EHRs) have further strengthened the value of these systems. Such innovations allow healthcare providers to access and interpret comprehensive patient data efficiently, ultimately supporting more informed and timely clinical decisions.
By End User Insights
Pharma and Bio-pharma Companies segment holds a leading position in the cardiac safety services market. This dominance is driven by the sector’s active role in developing and clinically testing cardiovascular drugs and therapies, which require thorough and reliable cardiac safety evaluations. The rise of personalized medicine has further increased the need for detailed cardiac monitoring to customize treatments according to individual patient profiles. Moreover, technological advancements such as real-time data analytics, advanced cardiac imaging, and integrated monitoring tools have significantly enhanced the precision and efficiency of cardiac assessments. These innovations make cardiac safety services essential for pharmaceutical and biopharmaceutical companies throughout the drug development process.
Regional Insights
The North American Cardiac Safety Services Market holds a prominent position globally, supported by a well-established healthcare infrastructure and strong regulatory oversight. In countries like the United States and Canada, there is a significant focus on improving diagnostic precision, enhancing patient safety, and minimizing the need for invasive procedures. This has led to increased adoption of advanced cardiac monitoring technologies, including ECG, Holter monitors, and telemetry systems with real-time data capabilities. These tools enable accurate cardiac risk detection and continuous patient monitoring, leading to more effective clinical decision-making. Additionally, organizations such as the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) actively support the integration of innovative cardiac safety solutions, recognizing their importance in personalized medicine and optimized clinical trial workflows. This favorable ecosystem continues to drive the adoption of cardiac safety services across hospitals, research centers, and pharmaceutical companies in the region.
Market Competitive Landscape
The Global Cardiac Safety Services has major players, including Biotrial, Celerion, Certara, Charles River Laboratories, Clario, Eurofins Scientific, ICON Plc, IQVIA, Koninklije Philips N.V, Laboratory Corporation of America Holdings, Medpace, Nova Research Laboratories, PPD Inc, Richmond Pharmacology, SGS S.A, and Wuxi AppTec. These companies compete fiercely with each other and local firms that have strong distribution networks and knowledge of suppliers and regulations. Medpace Holdings, Inc, founded in 1992 and headquartered in Cincinnati, Ohio, is a leading global clinical contract research organization (CRO) specializing in the provision of comprehensive development services to the biotechnology, pharmaceutical, and medical device industries. Medpace is recognized for its scientific expertise and integrated approach to managing complex clinical trials, particularly in therapeutic areas requiring cardiac safety evaluations.
Recent Developments:
In May 2024, Vivalink has introduced an advanced technology solution for Holter monitoring and Mobile Cardiac Telemetry (MCT), integrating remote patient monitoring (RPM) capabilities with sophisticated arrhythmia detection algorithms. This innovative approach enhances real-time cardiac monitoring by enabling continuous, wireless data collection and analysis, supporting early detection of abnormal heart rhythms. Designed for both clinical and home-based settings, the solution offers improved patient comfort, streamlined workflows, and timely diagnostic insights for healthcare providers.
In March 2024, Wellysis, a digital healthcare company spun out from Samsung, has partnered with Artella Solutions to launch a remote cardiac monitoring service in the U.S. The service features the FDA-approved S-Patch ExL device, which allows continuous cardiac monitoring for up to 14 days using a single coin battery. This collaboration strengthens Wellysis’ offerings in the Extended Holter and Mobile Cardiac Telemetry (MCT) segments, enhancing remote patient care through compact, user-friendly, and clinically reliable monitoring technology. The partnership reflects a shared commitment to advancing cardiac diagnostics with innovative, long-duration monitoring solutions tailored for both clinical and ambulatory settings.
In November 2023, Wellysis has signed a supply agreement with a leading U.S.-based ECG service provider to support the initial deployment of its ‘S-Patch’ cardiac monitoring device in Texas, with future expansion planned for Arizona and Louisiana. This agreement marks a strategic step in strengthening Wellysis’ presence in the U.S. cardiac safety market, enabling broader access to its advanced wearable ECG technology. The rollout aims to enhance remote cardiac monitoring capabilities across key regions, supporting early detection and continuous assessment of cardiac conditions through user-friendly, long-duration monitoring solutions.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Service, By Type, By End User |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | Biotrial, Celerion, Certara, Charles River Laboratories, Clario, Eurofins Scientific, ICON Plc, IQVIA, Koninklije Philips N.V, Laboratory Corporation of America Holdings, Medpace, Nova Research Laboratories, PPD Inc, Richmond Pharmacology, SGS S.A, Wuxi AppTec. |
Key Topics Covered in the Report
- Global Cardiac Safety Services Market Size (FY’2021-FY’2034)
- Overview of Global Cardiac Safety Services Market
- Segmentation of Global Cardiac Safety Services Market by Service (ECG/Holter Monitors, Blood Pressure Monitors, Cardiovascular Imaging, Others)
- Segmentation of Global Cardiac Safety Services Market by Type (Integrated, Standalone)
- Segmentation of Global Cardiac Safety Services Market by End User (Pharma and Bio-Pharma Companies, CROs, Others)
- Statistical Snap of Global Cardiac Safety Services Market
- Expansion Analysis of Global Cardiac Safety Services Market
- Problems and Obstacles in Global Cardiac Safety Services Market
- Competitive Landscape in the Global Cardiac Safety Services Market
- Details on Current Investment in Global Cardiac Safety Services Market
- Competitive Analysis of Global Cardiac Safety Services Market
- Prominent Players in the Global Cardiac Safety Services Market
- SWOT Analysis of Global Cardiac Safety Services Market
- Global Cardiac Safety Services Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1.Introduction
1.1.Scope of the report1.2.Market segment analysis
2.Research Methodology
2.1.Research data source
2.1.1.Secondary Data2.1.2.Primary Data2.1.3.SPERs internal database2.1.4.Premium insight from KOLs
2.2.Market size estimation
2.2.1.Top-down and Bottom-up approach
2.3.Data triangulation
3.Executive Summary
4.Market Dynamics
4.1.Driver, Restraint, Opportunity and Challenges analysis
4.1.1.Drivers4.1.2.Restraints4.1.3.Opportunities4.1.4.Challenges
5.Market variable and outlook
5.1.SWOT Analysis
5.1.1.Strengths5.1.2.Weaknesses5.1.3.Opportunities5.1.4.Threats
5.2.PESTEL Analysis
5.2.1.Political Landscape5.2.2.Economic Landscape5.2.3.Social Landscape5.2.4.Technological Landscape5.2.5.Environmental Landscape5.2.6.Legal Landscape
5.3.PORTERs Five Forces
5.3.1.Bargaining power of suppliers5.3.2.Bargaining power of buyers5.3.3.Threat of Substitute5.3.4.Threat of new entrant5.3.5.Competitive rivalry
5.4.Heat Map Analysis
6.Competitive Landscape
6.1.Global Cardiac Safety Services Market Manufacturing Base Distribution, Sales Area, Product Type6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Cardiac Safety Services Market
7.Global Cardiac Safety Services Market, By Service (USD Million) 2021-2034
7.1.ECG/Holter Monitor7.2.Blood Pressure Monitor7.3.Cardiovascular Imaging7.4.Others
8.Global Cardiac Safety Services Market, By Type (USD Million) 2021-2034
8.1.Integrated8.2.Standalone
9.Global Cardiac Safety Services Market, By End User (USD Million) 2021-2034
9.1.Pharma and Bio-Pharma Companies9.2.CROs9.3.Others
10.Global Cardiac Safety Services Market, (USD Million) 2021-2034
10.1.Global Cardiac Safety Services Market Size and Market Share
11.Global Cardiac Safety Services Market, By Region, (USD Million) 2021-2034
11.1.Asia-Pacific
11.1.1.Australia11.1.2.China11.1.3.India11.1.4.Japan11.1.5.South Korea11.1.6.Rest of Asia-Pacific
11.2.Europe
11.2.1.France11.2.2.Germany11.2.3.Italy11.2.4.Spain11.2.5.United Kingdom11.2.6.Rest of Europe
11.3.Middle East and Africa
11.3.1.Kingdom of Saudi Arabia11.3.2.United Arab Emirates11.3.3.Qatar11.3.4.South Africa11.3.5.Egypt11.3.6.Morocco11.3.7.Nigeria11.3.8.Rest of Middle-East and Africa
11.4.North America
11.4.1.Canada11.4.2.Mexico11.4.3.United States
11.5.Latin America
11.5.1.Argentina11.5.2.Brazil11.5.3.Rest of Latin America
12.Company Profile
12.1.Biotrial
12.1.1.Company details12.1.2.Financial outlook12.1.3.Product summary12.1.4.Recent developments
12.2.Celerion
12.2.1.Company details12.2.2.Financial outlook12.2.3.Product summary12.2.4.Recent developments
12.3.Certara
12.3.1.Company details12.3.2.Financial outlook12.3.3.Product summary12.3.4.Recent developments
12.4.Charles River Laboratories
12.4.1.Company details12.4.2.Financial outlook12.4.3.Product summary12.4.4.Recent developments
12.5.Clario
12.5.1.Company details12.5.2.Financial outlook12.5.3.Product summary12.5.4.Recent developments
12.6.Eurofins Scientific
12.6.1.Company details12.6.2.Financial outlook12.6.3.Product summary12.6.4.Recent developments
12.7.ICON Plc
12.7.1.Company details12.7.2.Financial outlook12.7.3.Product summary12.7.4.Recent developments
12.8.IQVIA
12.8.1.Company details12.8.2.Financial outlook12.8.3.Product summary12.8.4.Recent developments
12.9.Koninklije Philips N.V
12.9.1.Company details12.9.2.Financial outlook12.9.3.Product summary12.9.4.Recent developments
12.10.Laboratory Corporation of America Holdings
12.10.1.Company details12.10.2.Financial outlook12.10.3.Product summary12.10.4.Recent developments
12.11.Medpace
12.11.1.Company details12.11.2.Financial outlook12.11.3.Product summary12.11.4.Recent developments
12.12.Nova Research Laboratories
12.12.1.Company details12.12.2.Financial outlook12.12.3.Product summary12.12.4.Recent developments
12.13.PPD Inc
12.13.1.Company details12.13.2.Financial outlook12.13.3.Product summary12.13.4.Recent developments
12.14.Richmond Pharmacology
12.14.1.Company details12.14.2.Financial outlook12.14.3.Product summary12.14.4.Recent developments
12.15.SGS S.A
12.15.1.Company details12.15.2.Financial outlook12.15.3.Product summary12.15.4.Recent developments
12.16.Wuxi AppTec
12.16.1.Company details12.16.2.Financial outlook12.16.3.Product summary12.16.4.Recent developments
12.17.Others
13.Conclusion
14.List of Abbreviations
15.Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Cardiac Safety Services Market is projected to reach USD 3118.99 million by 2034, growing at a CAGR of 12.34% during the forecast period.
Cardiac Safety Services Market size from 2025. The Market is expected to reach USD 3118.99 million by 2034, at a CAGR of 12.34% during the forecast period.
Cardiac Safety Services Market CAGR of 12.34% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Cardiac Safety Services Market size is USD 3118.99 million from 2025 to 2034.
Cardiac Safety Services Market covered By Service, By Type, By End User
The North America is anticipated to have the highest Market share in the Cardiac Safety Services Market.
Biotrial, Celerion, Certara, Charles River Laboratories, Clario, Eurofins Scientific, ICON Plc, IQVIA, Koninklije Philips N.V, Laboratory Corporation of America Holdings, Medpace, Nova Research Laboratories, PPD Inc, Richmond Pharmacology, SGS S.A, Wuxi AppTec.
The report includes an in-depth analysis of the Global Cardiac Safety Services Market, including market size and trends, product mix, Applications, and supplier analysis.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
